HCPCS Codes Similar to Q2057

HCPCS Codes Similar to “Q2057” Code.
Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose

C9073 Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20210101 Code effective date: 20210401 TXT \| PDF \| XML \| JSON	C9098 Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20220701 Code effective date: 20221001 TXT \| PDF \| XML \| JSON
C9301 Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20250401 Code effective date: 20250701 TXT \| PDF \| XML \| JSON	Q2053 Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20210401 Code effective date: 20210401 TXT \| PDF \| XML \| JSON
Q2056 Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20221001 Code effective date: 20221001 TXT \| PDF \| XML \| JSON	Q2058 Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion Code added date: 20250701 Code effective date: 20250701 TXT \| PDF \| XML \| JSON
C9076 Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20210701 Code effective date: 20211001 TXT \| PDF \| XML \| JSON	C9081 Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20211001 Code effective date: 20220101 TXT \| PDF \| XML \| JSON
Q2040 Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion Code added date: 20180101 Code effective date: 20190101 TXT \| PDF \| XML \| JSON	Q2041 Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20180401 Code effective date: 20190101 TXT \| PDF \| XML \| JSON
Q2042 Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20190101 Code effective date: 20190101 TXT \| PDF \| XML \| JSON	Q2054 Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20211001 Code effective date: 20211001 TXT \| PDF \| XML \| JSON
Q2055 Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Code added date: 20220101 Code effective date: 20240404 TXT \| PDF \| XML \| JSON	Q2043 Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion Code added date: 20110701 Code effective date: 20110701 TXT \| PDF \| XML \| JSON